Shares of Voyager Therapeutics Inc. (NASDAQ:VYGR) shot up 5.9% during trading on Thursday . The company traded as high as $15.17 and last traded at $15.11, with a volume of 52,890 shares traded. The stock had previously closed at $14.27.

A number of research firms have recently commented on VYGR. Stifel Nicolaus began coverage on shares of Voyager Therapeutics in a research note on Thursday, July 14th. They set a “buy” rating and a $33.00 target price for the company. Piper Jaffray Cos. reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Cowen and Company reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Finally, Wells Fargo & Co. began coverage on shares of Voyager Therapeutics in a research note on Friday, May 20th. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $30.25.

The firm’s 50-day moving average is $12.83 and its 200-day moving average is $11.61. The stock’s market cap is $431.46 million.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Thursday, May 12th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.67. Equities research analysts predict that Voyager Therapeutics Inc. will post ($1.46) earnings per share for the current fiscal year.

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.